In late 2023, the FDA moved 19 widely-used research peptides from Category 1 — legally compoundable with a physician's prescription — to Category 2, which effectively banned them from licensed compounding pharmacies. The FDA cited immunogenicity concerns, manufacturing impurity risks, and insufficient large-scale human clinical data as the basis for the restriction. For researchers, clinicians, and individuals who had relied on compounding access, the reclassification created an abrupt and significant gap.
Then, on February 27, 2026, U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. announced that approximately 14 of those 19 peptides would be moved back to Category 1, restoring legal compounding access via licensed pharmacies with a physician's prescription. Kennedy framed the reversal as part of an ongoing scientific review and broader regulatory reform under his leadership at HHS.
The Critical Distinction: Announcement vs. Formal Rule Change
Important as of April 6, 2026: No compounding pharmacy can legally produce these peptides until the FDA formally publishes the updated Category 1 list. The February 27 announcement was a policy direction statement, not a final regulatory action. Kennedy indicated the formal publication would come within weeks of the announcement — but as of this writing, it has not been released.
This distinction matters enormously in practice. A policy announcement from the HHS Secretary does not change the regulatory text. Compounding pharmacies operate under strict federal compliance requirements and cannot legally resume production of Category 2 peptides based on an announcement alone. Until the FDA publishes the updated list in the Federal Register or equivalent formal channel, the legal status of these peptides remains unchanged for compounders.
Individuals and clinicians who are waiting for access should monitor the FDA's official communications — not news coverage or third-party sources — for confirmation that the formal rule change has taken effect.
Which Peptides Are Expected to Return to Category 1
Based on Kennedy's announcement and subsequent reporting, approximately 14 of the original 19 Category 2 peptides are expected to regain compounding access. The following are among those anticipated to return, along with their current evidence classification:
- BPC-157 — Evidence Level D/C. Body Protection Compound 157 has an extensive preclinical and animal research base, with data suggesting roles in tissue repair, gut health, and joint recovery. As of April 2026, no published human randomized controlled trial exists. Animal model findings are promising but cannot be extrapolated to confirmed human therapeutic benefit.
- TB-500 (Thymosin Beta-4) — Evidence Level D. Animal studies indicate potential roles in wound healing, cardiac tissue recovery, and angiogenesis. Human data is very limited. Research suggests meaningful effects in preclinical models, but human RCT evidence has not been established.
- Thymosin Alpha-1 — Evidence Level B. This is among the better-studied peptides on the list. Human clinical data exists for immune modulation in the context of hepatitis B, hepatitis C, and post-chemotherapy immune recovery. It is approved as a pharmaceutical agent in several countries outside the United States.
- CJC-1295 — Evidence Level C. A growth hormone-releasing hormone (GHRH) analogue with human data supporting growth hormone secretagogue effects. Long-term human studies are limited, and its regulatory status is research-only in the United States.
- Ipamorelin — Evidence Level C. A selective growth hormone secretagogue with some human data. Often combined with CJC-1295 in research protocols. Long-term safety and efficacy data in humans remains limited.
- AOD-9604 — Evidence Level C. A fragment of human growth hormone studied for fat metabolism. Some human trial data exists from earlier obesity research programs, though it was not approved as a pharmaceutical.
- Selank — Evidence Level C. A synthetic analogue of tuftsin with anxiolytic properties studied in Russian clinical research. Limited peer-reviewed English-language human data.
- Semax — Evidence Level C. A ACTH-derived peptide studied for cognitive and neuroprotective effects, with more established use in Russian medicine. Limited Western RCT data.
- KPV — Evidence Level D/C. A tripeptide with preclinical evidence for anti-inflammatory effects, particularly in gut research models. Human data is sparse.
- GHK-Cu — Evidence Level C. A copper peptide with research interest in skin biology and wound healing. Some human skin application data exists, though systemic use data is limited.
Approximately 5 peptides from the original 19 are expected to remain in Category 2, likely due to stronger safety concerns or weaker human data profiles. The formal FDA publication will clarify the final list.
What Category 1 Status Actually Means
Returning to Category 1 does not mean these peptides are FDA-approved drugs. Several critical distinctions apply:
- Category 1 ≠ FDA approval. These remain unapproved compounds for off-label use, accessible only through licensed compounding pharmacies with a physician's prescription. They have not passed the FDA's drug approval process.
- Physician prescription required. Compounded peptides are not and will not be available over the counter. A licensed physician must evaluate and prescribe.
- Compounding pharmacy ≠ pharmaceutical-grade manufacturing. Quality standards at compounding pharmacies vary. Compounded preparations are not subject to the same manufacturing controls as FDA-approved drugs. Purity, potency, and sterility standards differ across facilities.
- WADA prohibited list is separate from FDA compounding status. For competitive athletes, the World Anti-Doping Agency's prohibited list governs what substances may be used. Many of the peptides expected to return to Category 1 — including BPC-157, TB-500, and growth hormone secretagogues — remain on the WADA prohibited list regardless of compounding legality in the United States.
What to Do While Awaiting the Formal Rule Change
For individuals who are interested in these peptides based on research interest or clinical consultation:
- Wait for the FDA's formal publication before assuming any compounding pharmacy access is legal.
- Consult a licensed physician who specializes in peptide research and compounding medicine. A qualified physician can monitor the regulatory update and advise appropriately once the formal change takes effect.
- Do not rely on gray-market or unverified online sources. Purity and identity of peptides purchased outside licensed compounding channels cannot be verified.
The regulatory landscape for research peptides in the United States is evolving quickly. The February 2026 announcement represents a meaningful policy shift, but it is not yet a completed regulatory action. PeptideWise will update this post when the FDA formally publishes the updated Category 1 list.
This article is for informational and educational purposes only. Nothing here constitutes medical advice, treatment recommendation, or encouragement to use any substance without appropriate medical supervision. Always consult a licensed healthcare provider.